Basu Rajit K, Kaddourah Ahmad, Terrell Tara, Mottes Theresa, Arnold Patricia, Jacobs Judd, Andringa Jennifer, Goldstein Stuart L
BMC Nephrol. 2015 Feb 26;16:24. doi: 10.1186/s12882-015-0016-6.
Acute kidney injury (AKI) is associated with poor outcome in critically ill children. While data extracted from retrospective study of pediatric populations demonstrate a high incidence of AKI, the literature lacks focused and comprehensive multicenter studies describing AKI risk factors, epidemiology, and outcome. Additionally, very few pediatric studies have examined novel urinary biomarkers outside of the cardiopulmonary bypass population.
METHODS/DESIGN: This is a prospective observational study. We anticipate collecting data on over 5000 critically ill children admitted to 31 pediatric intensive care units (PICUs) across the world during the calendar year of 2014. Data will be collected for seven days on all children older than 90 days and younger than 25 years without baseline stage 5 chronic kidney disease, chronic renal replacement therapy, and outside of 90 days of a kidney transplant or from surgical correction of congenital heart disease. Data to be collected includes demographic information, admission diagnoses and co-morbidities, and details on fluid and vasoactive resuscitation used. The renal angina index will be calculated integrating risk factors and early changes in serum creatinine and fluid overload. On days 2-7, all hemodynamic and pertinent laboratory values will be captured focusing on AKI pertinent values. Daily calculated values will include % fluid overload, fluid corrected creatinine, and KDIGO AKI stage. Urine will be captured twice daily for biomarker analysis on Days 0-3 of admission. Biomarkers to be measured include neutrophil gelatinase lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (l-FABP), and interleukin-18 (IL-18). The primary outcome to be quantified is incidence rate of severe AKI on Day 3 (Day 3-AKI). Prediction of Day 3-AKI by the RAI and after incorporation of biomarkers with RAI will be analyzed.
The Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology (AWARE) study, creates the first prospective international pediatric all cause AKI data warehouse and biologic sample repository, providing a broad and invaluable resource for critical care nephrologists seeking to study risk factors, prediction, identification, and treatment options for a disease syndrome with high associated morbidity affecting a significant proportion of hospitalized children.
ClinicalTrials.gov: NCT01987921.
急性肾损伤(AKI)与危重症儿童的不良预后相关。虽然从儿科人群回顾性研究中提取的数据显示AKI发病率较高,但文献中缺乏描述AKI危险因素、流行病学及预后的针对性强且全面的多中心研究。此外,极少有儿科研究在体外循环人群之外研究新型尿液生物标志物。
方法/设计:这是一项前瞻性观察性研究。我们预计在2014日历年收集全球31个儿科重症监护病房(PICU)收治的5000多名危重症儿童的数据。将对所有年龄大于90天且小于25岁、无基线5期慢性肾脏病、未接受慢性肾脏替代治疗、不在肾移植90天内或先天性心脏病手术矫正后90天内的儿童收集7天的数据。收集的数据包括人口统计学信息、入院诊断及合并症,以及所用液体和血管活性药物复苏的详细情况。将综合危险因素以及血清肌酐和液体超负荷的早期变化计算肾绞痛指数。在第2至7天,将获取所有血流动力学及相关实验室值,重点关注与AKI相关的值。每日计算值将包括液体超负荷百分比、液体校正肌酐和KDIGO AKI分期。入院第0至3天,每天收集两次尿液用于生物标志物分析。要检测的生物标志物包括中性粒细胞明胶酶载脂蛋白(NGAL)、肾损伤分子-1(KIM-1)、肝型脂肪酸结合蛋白(l-FABP)和白细胞介素-18(IL-18)。要量化的主要结局是第3天严重AKI的发生率(第3天AKI)。将分析肾绞痛指数(RAI)以及将生物标志物与RAI结合后对第3天AKI的预测情况。
全球急性肾损伤、肾绞痛与流行病学评估(AWARE)研究创建了首个前瞻性国际儿科全因AKI数据仓库和生物样本库,为重症监护肾脏病学家提供了一个广泛且宝贵的资源,有助于他们研究一种发病率高且影响相当比例住院儿童的疾病综合征的危险因素、预测、识别及治疗方案。
ClinicalTrials.gov:NCT01987921。